These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 15870949)

  • 1. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
    Warnecke-Eberz U; Hokita S; Xi H; Higashi H; Baldus SE; Metzger R; Brabender J; Bollschweiler E; Mueller RP; Dienes HP; Hoelscher AH; Schneider PM
    Oncol Rep; 2005 Jun; 13(6):1241-6. PubMed ID: 15870949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
    Xi H; Baldus SE; Warnecke-Eberz U; Brabender J; Neiss S; Metzger R; Ling FC; Dienes HP; Bollschweiler E; Moenig S; Mueller RP; Hoelscher AH; Schneider PM
    Clin Cancer Res; 2005 Dec; 11(23):8341-7. PubMed ID: 16322294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.
    Warnecke-Eberz U; Metzger R; Miyazono F; Baldus SE; Neiss S; Brabender J; Schaefer H; Doerfler W; Bollschweiler E; Dienes HP; Mueller RP; Danenberg PV; Hoelscher AH; Schneider PM
    Clin Cancer Res; 2004 Jun; 10(11):3794-9. PubMed ID: 15173087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
    Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
    J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
    Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
    Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative analysis of survivin RNA expression in blood as a non-invasive predictor of response to neoadjuvant radiochemotherapy in esophageal cancer.
    Grimminger P; Vallböhmer D; Hoffmann A; Schulte C; Bollschweiler E; Schneider PM; Hölscher AH; Metzger R; Brabender J
    J Surg Oncol; 2009 Nov; 100(6):447-51. PubMed ID: 19653263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High orotate phosphoribosyltransferase gene expression predicts complete response to chemoradiotherapy in patients with squamous cell carcinoma of the esophagus.
    Kajiwara T; Nishina T; Hyodo I; Moriwaki T; Endo S; Nasu J; Hori S; Matsuura B; Hiasa Y; Onji M
    Oncology; 2009; 76(5):342-9. PubMed ID: 19307741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.
    Joshi MB; Shirota Y; Danenberg KD; Conlon DH; Salonga DS; Herndon JE; Danenberg PV; Harpole DH
    Clin Cancer Res; 2005 Mar; 11(6):2215-21. PubMed ID: 15788669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prediction of response to neoadjuvant chemotherapy in Barrett's carcinoma by quantitative gene expression analysis].
    Langer R; Specht K; Becker K; Ewald P; Sarbia M; Busch R; Feith M; Stein HJ; Siewert JR; Höfler H
    Verh Dtsch Ges Pathol; 2004; 88():207-13. PubMed ID: 16892554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survivin expression in gastric cancer: Association with histomorphological response to neoadjuvant therapy and prognosis.
    Vallböhmer D; Drebber U; Schneider PM; Baldus S; Bollschweiler E; Brabender J; Warnecke-Eberz U; Mönig S; Hölscher AH; Metzger R
    J Surg Oncol; 2009 Jun; 99(7):409-13. PubMed ID: 19347901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer.
    Schneider PM; Metzger R; Schaefer H; Baumgarten F; Vallbohmer D; Brabender J; Wolfgarten E; Bollschweiler E; Baldus SE; Dienes HP; Hoelscher AH
    Ann Surg; 2008 Dec; 248(6):902-8. PubMed ID: 19092334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance.
    Su L; Wang Y; Xiao M; Lin Y; Yu L
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct; 110(4):484-91. PubMed ID: 20868995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer.
    Miyazono F; Metzger R; Warnecke-Eberz U; Baldus SE; Brabender J; Bollschweiler E; Doerfler W; Mueller RP; Dienes HP; Aikou T; Hoelscher AH; Schneider PM
    Br J Cancer; 2004 Aug; 91(4):666-72. PubMed ID: 15213712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer.
    Prenzel KL; König A; Schneider PM; Schnickmann C; Baldus SE; Schröder W; Bollschweiler E; Dienes HP; Mueller RP; Izbicki JR; Hölscher AH
    Ann Surg Oncol; 2007 Feb; 14(2):954-9. PubMed ID: 17103071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma.
    Ikeguchi M; Kaibara N
    Br J Cancer; 2002 Oct; 87(8):883-7. PubMed ID: 12373603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Death-associated protein kinase (DAPK) promoter methylation and response to neoadjuvant radiochemotherapy in esophageal cancer.
    Brabender J; Arbab D; Huan X; Vallböhmer D; Grimminger P; Ling F; Neiss S; Bollschweiler E; Schneider PM; Hölscher AH; Metzger R
    Ann Surg Oncol; 2009 May; 16(5):1378-83. PubMed ID: 19224282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expression in advanced non-small-cell lung cancer patients.
    Chen P; Li J; Ge LP; Dai CH; Li XQ
    Respirology; 2010 Apr; 15(3):501-9. PubMed ID: 20210890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of preoperative radiochemotherapy on postoperative course and survival in patients with locally advanced squamous cell oesophageal carcinoma.
    Mariette C; Piessen G; Lamblin A; Mirabel X; Adenis A; Triboulet JP
    Br J Surg; 2006 Sep; 93(9):1077-83. PubMed ID: 16779882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy.
    Tanaka K; Mohri Y; Ohi M; Yokoe T; Koike Y; Morimoto Y; Miki C; Tonouchi H; Kusunoki M
    Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):639-46. PubMed ID: 18691855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.